Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Nevro (NVRO) Share Price
News headlines about Nevro (NYSE:NVRO) have been trending somewhat positive on Thursday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nevro earned a news impact score of 0.10 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 47.8332424748895 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have impacted Accern’s analysis:
- Andrew H. Galligan Sells 7,000 Shares of Nevro (NVRO) Stock (americanbankingnews.com)
- Don’t Forget to Observe This Stock: Nevro Corp. (NVRO) (mosttradedstocks.com)
- Why Sell? Reason to know? Nevro Corp. (NVRO) (nysestocks.review)
- Keep an Eye On Featured Stock: Nevro Corp. (NVRO) (stockquote.review)
- Global Boston Scientific Market 2018 Share- Boston Scientific, Nevro, Medtronic (theexpertconsulting.com)
Several research firms recently commented on NVRO. ValuEngine lowered Nevro from a “hold” rating to a “sell” rating in a research note on Thursday. Northland Securities lowered Nevro from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 8th. Wells Fargo lowered Nevro from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 8th. Canaccord Genuity dropped their target price on Nevro from $110.00 to $102.00 and set a “buy” rating for the company in a research note on Tuesday, May 8th. Finally, Zacks Investment Research upgraded Nevro from a “sell” rating to a “hold” rating in a research note on Thursday, April 26th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. Nevro currently has an average rating of “Hold” and a consensus price target of $98.78.
Nevro (NYSE:NVRO) last announced its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.01). The firm had revenue of $97.96 million for the quarter, compared to analyst estimates of $96.87 million. Nevro had a negative return on equity of 16.32% and a negative net margin of 11.53%. The business’s revenue was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.34) earnings per share. research analysts predict that Nevro will post -1.2 EPS for the current fiscal year.
In other news, Director Wilfred E. Jaeger sold 42,116 shares of the stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $80.19, for a total value of $3,377,282.04. Following the completion of the sale, the director now owns 1,518 shares in the company, valued at $121,728.42. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Andrew H. Galligan sold 7,000 shares of the stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $80.10, for a total value of $560,700.00. The disclosure for this sale can be found here. Insiders have sold 241,116 shares of company stock valued at $19,446,802 over the last 90 days. 6.90% of the stock is currently owned by insiders.
Nevro Company Profile
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.